Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJ107 + Pembrolizumab in Advanced Solid Tumors
NCT05145907Phase 2Active, not recruiting
- Sponsor
- TJ Biopharma
- Start
- Dec 2021
- Primary completion
- Jun 2024
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efineptakin alfa in solid tumor, triple-negative breast cancer (TNBC) and head and neck squamous cell carcinoma (HNSCC), sponsored by TJ Biopharma. Primary endpoints: Rate of Adverse Events up to 2 years and Rate of Serious Adverse Events up to 2 years. Started Dec 2021; status: active, not recruiting.
02
Drugs
efineptakin alfa
03
Conditions
solid tumortriple-negative breast cancer (TNBC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05145907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05145907.